FOLH1 and prostate carcinoma: IMPLICATIONS FOR PATIENT CARE:177Lu-L804-IAB2MA is a promising candidate for treating PSMA-positive prostate cancer in humans, with the potential for comparable efficacy and an improved safety profile versus existing therapeutic agents.